当前位置： SCI文献检索 > PHARMACOGENOMICS期刊下所有文献 > Pharmacogenomics of beta2-agonist: key focus on signaling pathways.

Pharmacogenomics of beta2-agonist: key focus on signaling pathways.

Abstract：

:Asthma is one of the most common respiratory diseases, where inhalation and exhalation are obstructed due to narrowing of the airways by broncho-constriction or by inflammation. Among all the available anti-asthma therapies, beta2-agonists are the most effective bronchodilators available, and give rapid relief of asthma symptoms. Evidence suggests that the degree of beta2-agonist response varies greatly between patients and genetic factors have a major role in it. Despite several studies on the beta2-agonist pharmacogenetics, significant gaps in knowledge still remain and need to be resolved before the pharmacotyping of beta2-agonist responsiveness comes to clinical practice. As we know, beta2-agonists show their influence by targeting beta2-adrenergic receptors, leading to the activation of beta2-adrenergic receptors and its downstream cascade. Signaling through beta2-adrenergic receptors mediates numerous airway functions by regulating broncho-constriction and dilation pathways. Therefore, it is an important prerequisite to understand these pathways, which will assist in defining the variability in therapeutic responses for beta2-agonists. Owing to the complexity of the action of a beta2-agonist and its therapeutic response, a broader genomics approach will help in optimizing therapy for the individual patient. This might be achieved by considering and focusing on receptor/s at which the drug binds directly, signal transduction cascades or downstream proteins and proteins involved in the relaxation and constriction of the airway smooth muscle. Considering that a drug response may involve a large number of proteins, it seems unlikely that a single polymorphism or haplotype in a single gene would explain a high degree of drug response variability in a consistent fashion. Thus, it shows that a polygenic approach will be more appropriate. In order to follow this, the mode of action of the beta2-agonist and its downstream signaling cascade should essentially be assessed to resolve the beta2-agonist enigma.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Bhatnagar P,Guleria R,Kukreti R

doi

10.2217/14622416.7.6.919

subject

Has Abstract

pub_date

2006-09-01 00:00:00

pages

919-33

issue

eissn

1462-2416

issn

1744-8042

journal_volume

pub_type

杂志文章,评审

在线工具

Pharmacogenomics of beta2-agonist: key focus on signaling pathways.